Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Elite Pharmaceuticals (OTCQB: ELTP) has achieved a significant operational milestone with the first product shipment from its newly FDA-approved expanded campus in Northvale, New Jersey. The facility at 144 Ludlow Avenue features advanced packaging capabilities, inventory space, and warehouse facilities.
The highlight of the expansion is a state-of-the-art packaging line that can process approximately 120 bottles per minute. This development enables Elite to repurpose existing packaging areas into additional manufacturing suites, substantially boosting production capacity. The expansion is strategically designed to accommodate the company's projected packaging requirements for the next five years.
Elite Pharmaceuticals (OTCQB: ELTP) ha raggiunto un'importante pietra miliare operativa con la prima spedizione di prodotto dal suo nuovo campus ampliato, approvato dalla FDA, a Northvale, nel New Jersey. La struttura al 144 di Ludlow Avenue dispone di capacità avanzate di imballaggio, spazio per l'inventario e strutture di magazzino.
Il punto forte dell'espansione è una linea di imballaggio all'avanguardia che può elaborare circa 120 bottiglie al minuto. Questo sviluppo consente a Elite di riconvertire le aree di imballaggio esistenti in ulteriori suite di produzione, aumentando notevolmente la capacità produttiva. L'espansione è progettata strategicamente per soddisfare i requisiti di imballaggio previsti dall'azienda per i prossimi cinque anni.
Elite Pharmaceuticals (OTCQB: ELTP) ha logrado un hito operativo significativo con el primer envío de producto desde su nuevo campus ampliado, aprobado por la FDA, en Northvale, Nueva Jersey. La instalación en 144 Ludlow Avenue cuenta con capacidades avanzadas de envasado, espacio de inventario y instalaciones de almacén.
El aspecto más destacado de la expansión es una línea de envasado de última generación que puede procesar aproximadamente 120 botellas por minuto. Este desarrollo permite a Elite reconvertir las áreas de envasado existentes en suites de fabricación adicionales, aumentando sustancialmente la capacidad de producción. La expansión está diseñada estratégicamente para acomodar los requisitos de envasado proyectados de la empresa para los próximos cinco años.
엘리트 제약 (OTCQB: ELTP)는 뉴저지주 노스베일에 위치한 FDA 승인 신규 확장 캠퍼스에서 첫 번째 제품 출하를 통해 중요한 운영 이정표를 달성했습니다. 144 루드로우 애비뉴에 위치한 이 시설은 고급 포장 능력, 재고 공간 및 창고 시설을 갖추고 있습니다.
확장의 하이라이트는 분당 약 120병을 처리할 수 있는 최첨단 포장 라인입니다. 이 개발은 엘리트가 기존 포장 구역을 추가 제조 공간으로 재구성할 수 있게 하여 생산 능력을 크게 향상시킵니다. 이 확장은 향후 5년간 회사의 예상 포장 요구 사항을 수용하도록 전략적으로 설계되었습니다.
Elite Pharmaceuticals (OTCQB: ELTP) a atteint une étape opérationnelle significative avec la première expédition de produit de son nouveau campus élargi, approuvé par la FDA, à Northvale, dans le New Jersey. L'établissement situé au 144 Ludlow Avenue dispose de capacités d'emballage avancées, d'espace de stockage et d'installations d'entrepôt.
Le point fort de l'expansion est une ligne d'emballage à la pointe de la technologie capable de traiter environ 120 bouteilles par minute. Ce développement permet à Elite de réaffecter les zones d'emballage existantes en suites de fabrication supplémentaires, augmentant considérablement la capacité de production. L'expansion est stratégiquement conçue pour répondre aux exigences d'emballage projetées de l'entreprise pour les cinq prochaines années.
Elite Pharmaceuticals (OTCQB: ELTP) hat einen bedeutenden betrieblichen Meilenstein mit dem ersten Produktversand von seinem neu erweiterten, von der FDA genehmigten Campus in Northvale, New Jersey, erreicht. Die Einrichtung in der Ludlow Avenue 144 verfügt über fortschrittliche Verpackungskapazitäten, Lagerfläche und Lagerhäuser.
Das Highlight der Erweiterung ist eine hochmoderne Verpackungslinie, die etwa 120 Flaschen pro Minute verarbeiten kann. Diese Entwicklung ermöglicht es Elite, bestehende Verpackungsbereiche in zusätzliche Produktionsräume umzuwandeln und die Produktionskapazität erheblich zu steigern. Die Erweiterung ist strategisch darauf ausgelegt, die voraussichtlichen Verpackungsanforderungen des Unternehmens für die nächsten fünf Jahre zu erfüllen.
- First successful product shipment from new FDA-approved facility
- New packaging line capacity of 120 bottles/minute
- Conversion of existing packaging space into manufacturing suites
- Increased production capacity for 5-year growth plan
- None.
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus.
The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse space. The new packaging line utilizes the latest technology, capable of producing approximately 120 bottles per minute. This expansion allows for the conversion of existing packaging space into additional manufacturing suites, significantly increases the Company's current production capacity and positions the Company to meet its projected packaging demand for at least the next five years.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA-registered facility for research, development, and manufacturing in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242965
FAQ
What is the production capacity of Elite Pharmaceuticals' (ELTP) new packaging line?
Where is Elite Pharmaceuticals' (ELTP) new expanded facility located?
How long will Elite Pharmaceuticals' (ELTP) new facility meet packaging demands?
What improvements does ELTP's facility expansion bring to manufacturing capabilities?
